Kesimpta (ofatumumab)
- Region
- 🇪🇺 EU
- Active substance
- ofatumumab
- Company
- Novartis Europharm Limited
- Status
- Authorised
- Therapeutic area
- Multiple Sclerosis, Relapsing-Remitting
- EU approval
- Fri 26 Mar 2021
- Application
- EMEA/H/C/005410
- ATC
- L04AA52
- Official record
- www.ema.europa.eu
Indication
Kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features (see section 5.1).
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Arzerra Withdrawn · Novartis Europharm Ltd
Follow Kesimpta
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.